Ascelia Pharma AB (OSTO:ACE) 3-1 Month Momentum %: -73.07% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACE Ascelia Pharma AB OSTO:ACE
30 GF Score
Price kr0.61
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB 3-1 Month Momentum %?

Ascelia Pharma AB OSTO:ACE +0.38% 30 3-1 Month Momentum % is -73.07% as of Aug. 04, 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, Ascelia Pharma AB ranks worse than 98.78% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Ascelia Pharma AB's 3-1 Month Momentum % is -73.07%.

The industry rank for Ascelia Pharma AB's 3-1 Month Momentum % or its related term are showing as below:

OSTO:ACE's 3-1 Month Momentum % is ranked worse than
98.78% of 1393 companies
in the Biotechnology industry
Industry Median: -6.97 vs OSTO:ACE: -73.07

Ascelia Pharma AB  (OSTO:ACE) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Ascelia Pharma AB 3-1 Month Momentum % Related Terms


OSTO:ACE vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's 3-1 Month Momentum % falls into.


OSTO:ACE
30GF Score
Ascelia Pharma AB OSTO:ACE
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB  (OSTO:ACE) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -73.07% mean?
Ascelia Pharma AB (OSTO:ACE) has a 3-1 Month Momentum % of -73.07% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #1376 out of 1393 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Ascelia Pharma AB's 3-1 Month Momentum % too high?
Ascelia Pharma AB's current 3-1 Month Momentum % is -73.07%. Based on the distribution chart, Ascelia Pharma AB ranks #1376 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascelia Pharma AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #1376 out of 1393 companies for 3-1 Month Momentum %. This places Ascelia Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current 3-1 Month Momentum % is -73.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current 3-1 Month Momentum % of -73.07%. The current 3-1 Month Momentum % is -73.07%. Ascelia Pharma AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current 3-1 Month Momentum % is -73.07% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
30GF Score

Get the complete analysis for OSTO:ACE

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.61
Price